158 related articles for article (PubMed ID: 24706168)
1. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
2. Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020.
Seung SJ; Saherawala H; Moldaver D; Shokar S; Ammendolea C; Brezden-Masley C
Breast Cancer Res Treat; 2024 Apr; 204(2):341-357. PubMed ID: 38127177
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study.
Negri E; Zambelli A; Franchi M; Rossi M; Bonifazi M; Corrao G; Moja L; Zocchetti C; La Vecchia C
Oncologist; 2014 Dec; 19(12):1209-15. PubMed ID: 25355843
[TBL] [Abstract][Full Text] [Related]
4. Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
Geurts SME; Ibragimova KIE; Ding N; Meegdes M; Erdkamp F; Heijns JB; Tol J; Vriens BEPJ; Dercksen MW; Aaldering KNA; Pepels MJAE; van de Winkel L; Peters NAJB; van de Wouw AJ; Maaskant SAJG; Teeuwen-Dedroog NJA; van Nijnatten TJA; de Boer M; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2024 Jun; 205(2):287-302. PubMed ID: 38381274
[TBL] [Abstract][Full Text] [Related]
5. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.
Epaillard N; Lusque A; Jacot W; Mailliez A; Bachelot T; Arnedos M; Le Du F; Brain E; Ferrero JM; Massard V; Desmoulins I; Mouret-Reynier MA; Levy C; Gonçalves A; Leheurteur M; Petit T; Filleron T; Bosquet L; Pistilli B; Frenel JS
ESMO Open; 2024 May; 9(5):103447. PubMed ID: 38703431
[TBL] [Abstract][Full Text] [Related]
6. Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance.
Križić M; Popović M; Silovski T; Grbin D; Dedić Plavetić N
Drugs Real World Outcomes; 2024 Jun; ():. PubMed ID: 38879832
[TBL] [Abstract][Full Text] [Related]
7. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network.
Freedman RA; Hughes ME; Ottesen RA; Weeks JC; He Y; Wong YN; Theriault R; Keating NL
Cancer; 2013 Feb; 119(4):839-46. PubMed ID: 23011924
[TBL] [Abstract][Full Text] [Related]
8. Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities.
Zhou YT; Chu JH; Zhao SH; Li GL; Fu ZY; Zhang SJ; Gao XH; Ma W; Shen K; Gao Y; Li W; Yin YM; Zhao C
Acta Pharmacol Sin; 2024 Jun; 45(6):1287-1304. PubMed ID: 38360930
[TBL] [Abstract][Full Text] [Related]
9. NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer.
Korner EJ; Morris A; Allen IE; Hurvitz S; Beattie MS; Kalesan B
Syst Rev; 2015 Oct; 4():133. PubMed ID: 26428301
[TBL] [Abstract][Full Text] [Related]
10. HER2-positive male breast cancer: an update.
Ottini L; Capalbo C; Rizzolo P; Silvestri V; Bronte G; Rizzo S; Russo A
Breast Cancer (Dove Med Press); 2010 Oct; 2():45-58. PubMed ID: 24367166
[TBL] [Abstract][Full Text] [Related]
11. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.
Kuksis M; Gao Y; Tran W; Hoey C; Kiss A; Komorowski AS; Dhaliwal AJ; Sahgal A; Das S; Chan KK; Jerzak KJ
Neuro Oncol; 2021 Jun; 23(6):894-904. PubMed ID: 33367836
[TBL] [Abstract][Full Text] [Related]
12. The impact of baseline body mass index on clinical outcomes in metastatic breast cancer: a prospective study.
Alarfi H; Salamoon M; Kadri M; Alammar M; Haykal MA; Alseoudi A; Youssef LA
BMC Res Notes; 2017 Nov; 10(1):550. PubMed ID: 29096707
[TBL] [Abstract][Full Text] [Related]
13. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
Pagani O; Senkus E; Wood W; Colleoni M; Cufer T; Kyriakides S; Costa A; Winer EP; Cardoso F;
J Natl Cancer Inst; 2010 Apr; 102(7):456-63. PubMed ID: 20220104
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit.
Brunetto AT; Sarker D; Papadatos-Pastos D; Fehrmann R; Kaye SB; Johnston S; Allen M; De Bono JS; Swanton C
Br J Cancer; 2010 Aug; 103(5):607-12. PubMed ID: 20664586
[TBL] [Abstract][Full Text] [Related]
15. Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer.
Rocque GB; Gilbert A; Williams CP; Kenzik KM; Nakhmani A; Kandhare PG; Bhatia S; Burkard ME; Azuero A
JCO Clin Cancer Inform; 2020 Jun; 4():500-513. PubMed ID: 32479187
[TBL] [Abstract][Full Text] [Related]
16. The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling.
Schlam I; Church SE; Hether TD; Chaldekas K; Hudson BM; White AM; Maisonet E; Harris BT; Swain SM
J Transl Med; 2021 Nov; 19(1):480. PubMed ID: 34838031
[TBL] [Abstract][Full Text] [Related]
17. Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies.
Borstnar S; Bozovic-Spasojevic I; Cvetanovic A; Plavetic ND; Konsoulova A; Matos E; Popovic L; Popovska S; Tomic S; Vrdoljak E
Radiol Oncol; 2024 Jun; 58(2):258-267. PubMed ID: 38860691
[TBL] [Abstract][Full Text] [Related]
18. Complete response after treatment of breast cancer with isolated liver metastasis: a case report.
Zhang T; Liu Y; Yang L; Tian T
AME Case Rep; 2024; 8():28. PubMed ID: 38711900
[TBL] [Abstract][Full Text] [Related]
19. De novo versus recurrent metastatic breast cancer affects the extent of brain metastases.
Joo B; Kim JH; Ahn SG; Park M; Suh SH; Ahn SJ
J Neurooncol; 2024 Jun; ():. PubMed ID: 38865012
[TBL] [Abstract][Full Text] [Related]
20. A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer.
Magno E; Bussard KM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
